Renal cell carcinoma

Current Opinion in Oncology

Volumn 16, Issue 3, 2004, Pages 247-252

  Rathmell, W Kimryn ^a   Godley, Paul A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Renal cell carcinoma; Vascular endothelial growth factor; Von Hippel Lindau

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CANCER VACCINE; CAPECITABINE; ENDOTHELIAL CELL GROWTH FACTOR; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 12; INTERLEUKIN 2; IRINOTECAN; SEMAXANIB; ZOLEDRONIC ACID;

ANGIOGENESIS; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CATHETER ABLATION; CLEAR CELL CARCINOMA; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

CARCINOMA, RENAL CELL; FORECASTING; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; UNITED STATES;

EID: 2142769628     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200405000-00010     Document Type: Review

References (63)

1. Cancer Facts and Figures 2003. Atlanta: American Cancer Society, Inc., 2003.
2. Kaelin WG Jr: The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol 2003, 14:2703-2711. This review thoroughly describes the current molecular understanding of von Hippel-Lindau activity as it pertains to kidney cancer.
3. Wiesener MS, Munchenhagen PM, Berger I, et al.: Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001, 61:5215-5222.
4. George DJ, Kaelin WG Jr: The von Hippel-Lindau protein, vascular endotheliel growth factor, and kidney cancer. N Engl J Med 2003, 349:419-421. This editorial review provides additional rationale for the activity of anti-VEGF anti-body bevacizumab in advanced RCC.
5. Hu CJ, Wang LY, Chodosh LA, et al.: Differential roles of hypoxia-inducible factor 1a (HIF-1a) and HIF-2a in hypoxic geno regulation. Molec Cell Biol 2003, 23:9361-9374.
6. Yeung RS, Xiao GH, Everitt JI, et al.: Allelic loss at the tuberous sclerosis 2 locus in spontaneous tumore in the Eker rat. Mol Carcinog 1995, 14:28-36.
7. Liu MY, Poellinger L, Walker CL: Up-regulation of bypoxa-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res 2003, 63:2675-2680.
8. Brugarolas JB, Vazquez F, Reddy A, et al.: TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003, 4:147-158.
9. Tomlinson IP, Alam NA, Rowan AJ, et al.: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002, 30:406-410.
10. Yao M, Yoshida M, Kishida T, et al.: VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002, 94:1569-1575.
11. Bui MH, Seligson D, Han KR, et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003, 9:802-811.
12. Miyata Y, Koga S, Kanda S, et al.: Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 2003, 9:1741-1749.
13. Palapattu GS, Pantuck AJ, Dorey F, et al.: Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. J Urol 2003; 170:768-772; discussion 772.
14. Leibovich BC, Blute ML, Cheville JC, et al.: Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 97:1663-1671. This study presents a stratification tool based on commonly documented tumor characteristics that adds prognostic value in earlier stage lesions.
15. Han KR, Pantuck AJ, Bui MH, et al.: Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003, 61:314-319.
16. Cheville JC, Lohse CM, Zincke H, et al.: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003, 27:612-624.
17. Zisman A, Chao DH, Pantuck AJ, et al.: Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype. J Urol 2002, 168:950-955.
18. Higgins JP, Shinghal R, Gill H, et al.: Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 2003, 162:925-932.
19. Zatyka M, da Silva NF, Clifford SC, et al.: Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Ras 2002, 62:3803-3811.
20. Yamazaki K, Sakamoto M, Ohta T, et al.: Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003, 22:847-852.
21. Vasselli JR, Shih JH, Iyengar SR, et al.: Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A 2003, 100:6958-6963.
22. Wilhelm M, Veltman JA, Olshen AB, et al.: Array-based comparative genomic hybridization for the differentiel diagnosis of renal cell cancer. Cancer Res 2002, 62:957-960.
23. Junker K, Weirich G, Amin MB, et al.: Genetic subtyping of renal cell carcinoma by comparative genomic hybridization. Recent Results Cancer Res 2003, 162:169-175.
24. Hedberg Y, Ljungberg B, Roos G, et al.: Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarrey. Br J Cancer 2003, 88:1417-1423.
25. Visapaa H, Bui M, Huang Y, et al.: Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology 2003, 61:845-850.
26. Unwin RD, Craven RA, Harnden P, et al.: Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003, 3:1620-1632.
27. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothehal growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434. This randomized phase II study demonstrated the clinical efficacy of VEGF-targeted therapy at least similar to that expected for standard therapy as a second-line agent with minimal toxicity.
28. Shaheen RM, Davis DW, Liu W, et al.: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999, 59:5412-5410.
29. Fong TA, Shawver LK, Sun L, et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kjnase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59:99-106.
30. Kuenen BC, Tabernero J, Baselga J, et al.: Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 2003, 9:1648-1655.
31. Lara PN Jr, Quinn DI, Margolin K, et al.: SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 2003, 9:4772-4781.
32. Wilhelm S, Chien DS: BAY 43-9006: preclinical data. Curr Pharm Des 2002, 8:2255-2257.
33. Campbell SC, Flanigan RC, Clark JI: Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol 2003, 4:363-372.
34. Chaudhary UB, Hull GW. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma. Oncology 2003, 17:701-705; discussion 705-706, 711-712.
35. Wood CG: The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin North Am 2003, 30:581-588.
36. Bex A, Horenblas S, de Gast GC: The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma. Technol Cancer Res Treat 2003, 2:205-210.
37. Baldwin DD, Dunbar JA, Parekh DJ, et al.: Single-center comparison of purely taparoscopic, hand-assisted laparoscopic, and open radical nephrectomy in patients at high anesthetic risk. J Endourol 2003, 17:161-167.
38. Klingler HC, Remzi M, Janetschek G, et al.: Benefits of laparoscopc renal surgery are more pronounced in patients with a high body mass index. Eur Urol 2003, 43:522-S27.
39. Gill IS, Matin SF, Desai MM, et al.: Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol 2003, 170:64-68.
40. Hsu TH, Jeffrey RB Jr, Chon C, et al.: Laparoacopic radical nephrectomy incorporating intraoperative ultrasonography for renal cell carcinoma with renal vein tumor thrombus. Urology 2003, 61:1246-1248.
41. Zelkovic PF, Resnick MI: Renal radiofrequency ablation: clinical status 2003. Curr Opin Urol 2003, 13:199-202.
42. Farrell MA, Charboneau WJ, DiMarco DS, et al.: Imaging-guided radiofrequency ablation of solid renal tumors. AJR Am J Roentgenol 2003, 180:1508-1513.
43. Gervais DA, Arellano RS, Mueller PR: Percutaneous radiofrequency ablation of nodal metastases. Cardiovasc Intervent Radiol 2002, 25:547-549.
44. Mayo-Smith WW, Dupuy DE, Parikh PM, et al.: Imaging-guided percutaneous radiofrequency ablation of solid renal masses: techniques and outcomes of 38 treatment sessions in 32 consecutive patients. AJR Am J Roentgenol 2003, 180:1503-1508.
45. Sternberg CN, Vogebang NJ: Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol 2003, 46(Suppl):105-115.
46. Atzpodien J, Hoffmann R, Franzke M, et al.: Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 2002, 95:1045-1050.
47. Atzpodien J, Kirchner H, Hanninen EL, et el.: Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993, 29A(Suppl 5):S6-S8.
48. Rathmell WK, Malkowicz BS, Holroyde C, et al.: A phase II trial of 5-flurouracil and leukovorin in combination with interferon-alpha and interteukin 2 in advanced renal cell cancer. Am J Clin Oncol, in press.
49. Rini BI, Vogelzang NJ, Dumas MC, et al.: Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000, 18:2419-2426.
50. Fizazi K, Rolland F, Chevreau C, et al.: A phase II study of irinotecan in patients with advanced renal cell carcinoma. Cancer 2003, 98:61-65.
51. Lipton A, Zheng M, Seaman J: Zoledronic acid delays the onset of skeletatrelated events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003, 98:962-969.
52. Yang JC, Sherry RM, Steinberg SM, et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003, 21:3127-3132. This randomized study addresses the controversial use of low-dose immunotherapy as a substitute for the highly toxic high-dose bolus regimen of IL-2 treatment. More durable complete responses were seen in the high-dose group, but complete responses were seen in all groups.
53. Ellerhorst JA, Hildebrand WH, Cavett JW, et al.: Heterozygosity or homozygosity for 2 HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated wrth cytokine therapy. J Urol 2003, 169:2084-2088.
54. Seliger B, Menig M, Lichtenfels R, et al.: Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy. Proteomics 2003, 3:979-990.
55. Messing EM, Manola J, Wilding G, et al.: Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003, 21:1214-1222. This study and the next one address the issue of immunotherapy in the adjuvant setting with negative results.
56. Clark JI, Atkins MB, Urba WJ, et al.: Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003, 21:3133-3140. See [55•].
57. Gollob JA, Veenstra KG, Parker RA, et al.: Phase I trial of concurrent twice-weekly recombinant human interteukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 2003, 21:2564-2573.
58. Vieweg J, Dannull J: Tumor vaccines: from gene therapy to dendritic cells: the emerging frontier. Urol Clin North Am 2003, 30:633-643. This paper reviews several of the available vaccine strategies being used in investigational treatment protocols for RCC.
59. Gitlitz BJ, Belldegrun AS, Zisman A, et al.: A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother 2003, 26:412-419.
60. Su Z, Dannull J, Heiser A, et al.: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003, 63:2127-2133.
61. Repmann R, Goldschmidt AJ, Richter A: Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Anticancer Res 2003, 23:969-974.
62. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, et al.: Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 2002, 25:500-508.
63. Pavlovich CP, Padilla-Nash H, Wangsa D, et al.: Patterns of aneuploidy in stage IV clear cell renal cell carcinoma revealed by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer 2003, 37:252-260.